SUPPLEMENTARY TABLE 2. Prespecified outcomes*,† for recombinant zoster vaccine (RZV) in reports submitted to the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All
i


SUPPLEMENTARY TABLE 2. Prespecified outcomes*,† for recombinant zoster vaccine (RZV) in reports submitted to the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018

Filetype[PDF-68.84 KB]


  • English
    • Details Supporting Files Related Documents You May Also Like

    Details:

    • Description:
      Supplementary table for: Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018.
    • Document Type:
      Table ;
    • Place as Subject:
      United States ;
    • Collection(s):
      Morbidity and Mortality Weekly Report (MMWR)
    • Main Document Checksum:
    • File Type:

    Related Documents

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov